MAM
STLN

Myriad Asset Management’s Starling Oncology STLN Stock Holding History

Myriad Asset Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-49,000
Closed -$509K – 93
2020
Q3 		$509K Buy
+49,000
New +$509K 0.11% 44

Other funds holding STLN

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SRCM
Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
ECM
Element Capital Management New York $3.2B AUM 29.54% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

Myriad Asset Management's STLN Position: Q4 2020 in Review

Myriad Asset Management sold out of Starling Oncology (STLN) in Q4 2020, closing a stake of 49,000 shares — an estimated $509K sold.

Myriad Asset Management first reported a position in STLN in Q3 2020 and held it in 1 quarter. The position peaked at $509K in Q3 2020. 49 funds tracked by Wall St. Rank hold STLN as of Q4 2020.

  • Myriad Asset Management reported no remaining Starling Oncology position as of Q4 2020 after selling out during the quarter.
  • Myriad Asset Management sold 49,000 Starling Oncology shares in Q4 2020, an estimated $509K.
  • Myriad Asset Management first reported a position in Starling Oncology in Q3 2020 and held it in 1 quarter.
  • Myriad Asset Management's Starling Oncology position peaked at $509K in Q3 2020.
  • 49 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2020.

Based on Myriad Asset Management's 13F filing for Q4 2020, filed 11 Feb 2021.